Share Prices & Company Research

Market News

29 Mar 2021 | 11:05

Karl Keegan appointed new e-therapeutics finance chief

(Sharecast News) - Network biology technology company e-therapeutics announced the appointment of Dr Karl Keegan as its chief financial officer in a non-board capacity with immediate effect on Monday. The AIM-traded firm said Dr Keegan had more than 20 years of experience in the pharmaceutical and biotech industries.

It said that after working in academia and large pharma, he became a sell-side analyst at a number of investment banks.

Since 2009, he held senior executive roles in private and public companies, most recently as chief executive officer of the privately-held Hox Therapeutics Limited.

"I am delighted to be joining the e-therapeutics team at such a pivotal time for the company," said Dr Karl Keegan.

"The company has built an impressive computational biology drug discovery platform and clinically validated RNA interference drug modality."

The board said Dr Keegan received his BSc in pharmacology from University College Dublin, MPhil and PhD degrees from the University of Cambridge, and his MSc in finance from the London Business School.

"We are delighted to welcome Karl to e-therapeutics at this point in the company's evolution," said CEO Ali Mortazavi.

"The combination of his industry and financial sector expertise will be a major addition to the team."

At 1604 BST, shares in e-therapeutics were down 4.23% at 21.5p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.